{"filing":{"accession_number":"0001104659-26-105598","cik":"0002072188","ticker":"BIOT","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-04","primary_document":"tm2624858d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2072188/000110465926105598/tm2624858d1_6k.htm"},"events":[{"id":31702,"run_id":29104,"accession_number":"0001104659-26-105598","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit is an operational update on the Company's Indonesia growth platform and product development initiatives, including securing a clinic premises in Jakarta, finalizing subscription pricing, and identifying cosmetic product candidates with manufacturing partners INVITRX and PARVA. The disclosure describes strategic business progress on multiple fronts (clinic site development, product formulation, manufacturing partnerships) that would affect a reasonable investor's assessment of the Company's execution on previously announced initiatives, but does not fit a specific named event type such as M\u0026A, earnings, or material litigation.","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","ticker":"BIOT","filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":34658,"accession_number":"0001104659-26-105598","item_number":"EX-99.1","item_title":"tm2624858d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is an operational update on the Company's Indonesia growth platform and product development initiatives, including securing a clinic premises in Jakarta, finalizing subscription pricing, and identifying cosmetic product candidates with manufacturing partners INVITRX and PARVA. The disclosure describes strategic business progress on multiple fronts (clinic site development, product formulation, manufacturing partnerships) that would affect a reasonable investor's assessment of the Company's execution on previously announced initiatives, but does not fit a specific named event type such as M\u0026A, earnings, or material litigation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:06:00.545355+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34658,"accession_number":"0001104659-26-105598","item_number":"EX-99.1","item_title":"tm2624858d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is an operational update on the Company's Indonesia growth platform and product development initiatives, including securing a clinic premises in Jakarta, finalizing subscription pricing, and identifying cosmetic product candidates with manufacturing partners INVITRX and PARVA. The disclosure describes strategic business progress on multiple fronts (clinic site development, product formulation, manufacturing partnerships) that would affect a reasonable investor's assessment of the Company's execution on previously announced initiatives, but does not fit a specific named event type such as M\u0026A, earnings, or material litigation.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-08T10:06:00.545355+00:00","company_name":"INSTINCT BIO TECHNICAL CO HOLDINGS INC.","ticker":"BIOT","filing_date":"2026-09-08"}]}